Novartis Exelon Alzheimer's therapy approved in Switzerland in under four months.
Executive Summary
NOVARTIS TO LAUNCH EXELON IN SWISS MARKET IN LATE AUGUST following fast-track approval of the acetylcholinesterase inhibitor Alzheimer's therapy by Switzerland's health authority, Interkantonale Kontrollstelle fuer Heilmittel, July 31. Novartis filed for Exelon (rivastigmin) approval with IKS, FDA and the European Medicines Evaluation Agency April 7; the drug's swift Swiss approval could presage quick review elsewhere. Exelon is indicated in Switzerland to treat mild to moderately severe Alzheimer's disease.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth